Serestherapeutics.com

Serestherapeutics.com has Server used 35.188.165.14 IP Address with Hostname in United States. Below listing website ranking, Similar Webs, Backlinks. This domain was first 2011-06-03 (10 years, 53 days) and hosted in Ann Arbor United States, server ping response time 52 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Serestherapeutics keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

1 Seres therapeutics
2 Seres therapeutics stock
3 Seres therapeutics ir
4 Seres therapeutics ceo
5 Seres therapeutics ipo
6 Seres therapeutics mcrb
7 Seres therapeutics news
8 Seres therapeutics logo
9 Seres therapeutics price

Hosting Provider

Website: Serestherapeutics.com
Hostname: 14.165.188.35.bc.googleusercontent.com
Country:
Region: MI
City: Ann Arbor
Postal Code: 48104
Latitude: 42.273399353027
Longitude: -83.713302612305
Area Code: 734
Email AbuseNo Emails Found

Find Other Domains on Any IP/ Domain


New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently

   » Orfit.com (1 seconds ago)

   » Bestblatt.com (14 seconds ago)

   » Alliance-uae.com (0 seconds ago)

   » Bommaritonissanballwin.com (4 seconds ago)

   » 3900americanriver.com (12 seconds ago)

   » Superstarseoacademy.com (17 seconds ago)

   » Serestherapeutics.com (0 seconds ago)

   » Texansgymnastics.com (16 seconds ago)

   » Mahoneygroupinc.com (8 seconds ago)

Results For Websites Listing

Found 43 Websites with content related to this domain, It is result after search with search engine

About Us – Seres Therapeutics

Serestherapeutics.com   DA: 25 PA: 10 MOZ Rank: 35

  • Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome
  • We are an exceptional team of drug development and microbiome experts.

Seres Therapeutics, Inc. (MCRB) Stock Price, News, Quote

Finance.yahoo.com   DA: 17 PA: 11 MOZ Rank: 29

  • Seres Therapeutics Inc (NASDAQ: MCRB) has inked a 5-million deal with Nestlé Health Science to commercialize SER-109 if it can win FDA approval
  • SER-109 is an oral, live microbiome therapy under

Seres Therapeutics, Inc. Company Profile Cambridge, MA

Dnb.com   DA: 11 PA: 50 MOZ Rank: 63

  • Seres Therapeutics specializes in microbiome therapeutics, which help restore health to persons whose have an unhealthy (or dysbiotic) microbiome ecology of microorganisms
  • It is developing biologic drugs to treat metabolic, inflammatory, and infectious diseases, primarily in the colon; its lead drug candidates are SER-109 for the treatment of

Seres Therapeutics Inc (MCRB) Quote

Morningstar.com   DA: 19 PA: 23 MOZ Rank: 45

  • Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States
  • The company is engaged in developing biological drugs which are referred as ecobiotic

Seres Therapeutics Announces Topline Results For SER-287

Finance.yahoo.com   DA: 17 PA: 50 MOZ Rank: 71

Seres Therapeutics (NASDAQ: MCRB) is a microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that interact with host cells and tissues to treat disease.

Seres Therapeutics Microbiome Drug Flunks Phase 2 Test In

Medcitynews.com   DA: 15 PA: 50 MOZ Rank: 70

  • 2 days ago · Seres Therapeutics’ ambitions to treat ulcerative colitis with a microbiome drug were dealt a setback as its experimental therapy failed in Phase 2 testing
  • The company plans a “rigorous

Seres Therapeutics To Present At Two Upcoming June

Businesswire.com   DA: 20 PA: 50 MOZ Rank: 76

  • is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to …

Careers At Seres Therapeutics, Inc.

Serestherapeutics.hrmdirect.com   DA: 31 PA: 27 MOZ Rank: 65

  • Careers At Seres Therapeutics, Inc
  • Share with friends or Subscribe! Even if you don’t see a job that’s a fit, but you’re excited by what Seres is doing and want to be a part of it, we’d appreciate hearing from you and will keep you in mind for a future opportunity.

MCRB Stock Price Seres Therapeutics Inc. Stock Quote (U

Marketwatch.com   DA: 19 PA: 21 MOZ Rank: 48

  • engages in the development of biological drugs through microbiome therapeutics platform
  • Its product pipeline includes SER-109, …

Company Seres Therapeutics News, Employees And Funding

Topionetworks.com   DA: 21 PA: 50 MOZ Rank: 80

  • Seres Therapeutics is a clinical stage biotherapeutic company focused on discovering and developing Ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome
  • Founded by Flagship VentureLabs, Seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome.

Why Seres Therapeutics Stock Is Crashing Today The

Fool.com   DA: 12 PA: 50 MOZ Rank: 72

  • Shares of Seres Therapeutics ( NASDAQ:MCRB) were crashing 57.3% lower as of 11 a.m
  • The steep decline came after the company announced top …

Unique Antibiotic Pipeline To Combat Gram-Negative

Sperotherapeutics.com   DA: 21 PA: 10 MOZ Rank: 42

  • Programs Designed to Address Unmet Needs in Bacterial Infections and Rare Diseases Spero Therapeutics’ antibiotic pipeline is focused on areas for which the unmet medical need is greatest, the biological rationale for treatment is clear, and for which there are few approved therapies, or where the standard of care is suboptimal
  • Our pipeline of anti-infective […]

Home Century Therapeutics

Centurytx.com   DA: 17 PA: 17 MOZ Rank: 46

PHILADELPHIA, June 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the pricing of its initial public offering of 10,550,000 shares of its common stock at a public offering price of $20.00 per share.

Seres Therapeutics’s Competitors, Revenue, Number Of

Owler.com   DA: 13 PA: 26 MOZ Rank: 52

  • Seres Therapeutics's revenue is the ranked 4th among it's top 10 competitors
  • The top 10 competitors average 203.2M
  • Over the last four quarters, Seres Therapeutics's revenue has decreased by 5.4%.

Seres Therapeutics, Inc. (NASDAQ:MCRB) Expected To

Marketbeat.com   DA: 18 PA: 50 MOZ Rank: 82

  • Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease
  • The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the

Seres Therapeutics Jobs, Employment Indeed.com

Indeed.com   DA: 14 PA: 31 MOZ Rank: 60

  • Cambridge, MA 02139 (Cambridgeport area) Easily apply
  • Reporting to the Sr Director, Supply Chain within the Commercial Manufacturing team, this role will be responsible for establishing and delivering sustainable…

Seres Therapeutics To Host Conference Call And Webcast To

Financialbuzz.com   DA: 21 PA: 50 MOZ Rank: 87

2 days ago · Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact

Director Information Technology

Serestherapeutics.hrmdirect.com   DA: 31 PA: 27 MOZ Rank: 75

  • Seres Therapeutics is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease.

Seres Therapeutics, Inc. Common Stock (MCRB) Pre-Market

Nasdaq.com   DA: 14 PA: 39 MOZ Rank: 71

Seres Therapeutics, Inc. Common Stock (MCRB) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.

Seres Therapeutics To Present At RBC Capital Markets 2021

Businesswire.com   DA: 20 PA: 29 MOZ Rank: 68

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to …

Seres Therapeutics To Host Conference Call And Webcast To

Biospace.com   DA: 16 PA: 50 MOZ Rank: 86

  • Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease
  • Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted

Seres Therapeutics, Nestlé Health Science Announce SER-109

Bloomberg.com   DA: 17 PA: 50 MOZ Rank: 88

About Seres Therapeutics Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of …

Seres Therapeutics VentureRadar

Ventureradar.com   DA: 20 PA: 50 MOZ Rank: 92

  • Seres Therapeutics Follow Following Location: USA
  • Private Company " Seres Health is a clinical stage biotherapeutic company focused on discovering and developing Ecobiotic® therapeutic products to treat important diseases by targeting the underlying biology of the human microbiome
  • Seres is pioneering the first therapeutics

Seres Therapeutics Employee Benefits And Perks Glassdoor

Glassdoor.com   DA: 17 PA: 50 MOZ Rank: 90

  • seres therapeutics to present at rbc capital markets 2021 global healthcare conference —30+ days ago CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 12, 2021--Seres Therapeutics, Inc
  • , (Nasdaq: MCRB), today announced that management will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on Tuesday, May 18

Seres Therapeutics : Announces David Arkowitz To Join As

Marketscreener.com   DA: 22 PA: 50 MOZ Rank: 96

  • Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease.

Analyst Ratings For Seres Therapeutics Markets Insider

Markets.businessinsider.com   DA: 27 PA: 50 MOZ Rank: 25

1 day ago · 6 analysts offering 12-month price targets in the last 3 months for Seres Therapeutics evaluate the company at an average price target of $23.5 with a …

Seres Therapeutics Jobs Glassdoor

Glassdoor.com   DA: 17 PA: 42 MOZ Rank: 85

  • SERES THERAPEUTICS TO PRESENT AT RBC CAPITAL MARKETS 2021 GLOBAL HEALTHCARE CONFERENCE —30+ days ago
  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 12, 2021--Seres Therapeutics, Inc
  • , (Nasdaq: MCRB), today announced that management will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on Tuesday, May 18

Why Seres Therapeutics Stock Surged Today The Motley Fool

Fool.com   DA: 12 PA: 50 MOZ Rank: 89

  • Shares of Seres Therapeutics (NASDAQ:MCRB) jumped 21% on Thursday after the biotech company announced the details of its capital raise

Seres Therapeutics Announces Topline Results For SER-287

Ih.advfn.com   DA: 12 PA: 50 MOZ Rank: 90

MCRB Seres Therapeutics Inc Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis -Primary endpoint of clinical remission compared to placebo was not achieved- -Both dosing regimens of SER-287 were generally well tolerated- -Open label and maintenance portions of the SER-287 stud

Analyst Ratings For Seres Therapeutics

Benzinga.com   DA: 16 PA: 50 MOZ Rank: 95

1 day ago · 6 analysts offering 12-month price targets in the last 3 months for Seres Therapeutics evaluate the company at an average price target of $23.5 with a …

Battered And Bruised Seres Therapeutics See Shares

Fiercebiotech.com   DA: 21 PA: 50 MOZ Rank: 20

Seres Therapeutics has endured a tough few years of trials setbacks, cuts and new management, but the GI biotech is hoping with its new set of broadly positive late-stage data it …

Seres Therapeutics Stock Plunges As Ulcerative Colitis

Msn.com   DA: 11 PA: 50 MOZ Rank: 92

Seres Therapeutics Inc (NASDAQ: MCRB) has announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to …

ImmunoPrecise Antibodies, PainReform Leads Healthcare

Seekingalpha.com   DA: 16 PA: 50 MOZ Rank: 98

ImmunoPrecise Antibodies IPA +88%, PainReform (PRFX) +48%, Seres Therapeutics MCRB -57%, Jupiter Wellness JUPW -24%

Associate II, Donor Recruiter Job In Cambridge, MA At

Ziprecruiter.com   DA: 20 PA: 50 MOZ Rank: 17

  • Easy 1-Click Apply (SERES THERAPEUTICS, INC.) Associate II, Donor Recruiter job in Cambridge, MA
  • View job description, responsibilities and qualifications

Lab Systems Manager, IT Job In Cambridge, MA At Seres

Ziprecruiter.com   DA: 20 PA: 50 MOZ Rank: 16

  • Within the Laboratories this position interacts with bench technologists, quality technologists, supervisors, managers, assistant directors, administrative director and the faculty directors
  • The incumbent also works with outside/Satellite laboratories or clinics and hospitals

Why Seres Therapeutics Stock Is Crashing Today Markets

Markets.businessinsider.com   DA: 27 PA: 50 MOZ Rank: 15

  • Shares of Seres Therapeutics (NASDAQ: MCRB) were crashing 57.3% lower as of 11 a.m
  • The steep decline came after the company announced top …

Recently Analyzed Sites

Orfit.com (1 seconds ago)

Bestblatt.com (14 seconds ago)

Alliance-uae.com (0 seconds ago)

3900americanriver.com (12 seconds ago)

Superstarseoacademy.com (17 seconds ago)

Serestherapeutics.com (0 seconds ago)

Texansgymnastics.com (16 seconds ago)

Mahoneygroupinc.com (8 seconds ago)

Millershowgoats.com (2 seconds ago)

Sacredheartofcicero.com (3 seconds ago)

Sherondental.com (13 seconds ago)

Zestybaguettebistro.com (1 seconds ago)

Millersconnect.com (13 seconds ago)

Genpore.com (5 seconds ago)